Skip to main content
  • Home
  • Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Topic:
  • CV Renal Metabolic
  • Heart Failure
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.

 

Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. 

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

 

This activity has been supported by an unrestricted educational grant from AstraZeneca.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists
  • General Cardiologists

Learning Objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
Register now Log in
1.

Welcome and Introduction

Duration:

Speakers: Felipe Martinez (Universidad Nacional de Córdoba, Córdoba, AR)

3.

DAPA-HF – Clinical Trial Design Rationale

Duration:

Speakers: Felipe Martinez (Universidad Nacional de Córdoba, Córdoba, AR)

4.

SGLT2i Beyond Diabetes – Mechanism of Benefit in CVD

Duration:

Speakers: Lars Lund (Karolinska Institutet, Stockholm, SE)

6.

The Dapagliflozin and Prevention of Adverse Outcomes in HF trial

Duration:

Speakers: Frank Ruschitzka (University hospital Zurich, Zurich, CH)

8.

Summary and Conclusions

Duration:

Speakers: Felipe Martinez (Universidad Nacional de Córdoba, Córdoba, AR)

Course Director

Felipe Martinez

National University of Cordoba, Cordoba, Argentina

Emeritus Professor of Medicine - Cordoba National University
Director - Instituto DAMIC-Fundación Rusculleda, Córdoba, Argentina
Fellow of the European Society of Cardiology (FESC)
Fellow of the American College of Cardiology (FACC)

View full profile

Speaker

Scott Solomon

Brigham and Women's Hospital, Boston, US / Harvard Medical School

Prof Scott D Solomon is the Edward D Frohlich Distinguished Chair at Harvard Medical School, Director of Noninvasive Cardiology and Senior Physician at Brigham and Women’s Hospital.

View full profile

Andrew Coats

Monash University, AU and University of Warwick, UK

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

View full profile

Carolyn Lam

National Heart Centre Singapore Duke-NUS, Singapore, SG

Dr Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in heart failure with preserved ejection fraction.

View full profile

Lars Lund

Karolinska Insitutet and Karolinska University Hospital, Sweden

Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.

View full profile

Frank Ruschitzka

University Heart Centre, University Hospital ZurichZurich, Switzerland

Professor Frank Ruschitzka, MD, FRCP (Edinburgh), FESC received his medical degree from the University of Gottingen in Germany in 1989. He specialized in internal medicine, nephrology and cardiology at the Universities of Gottingen and Zurich. 

View full profile

John McMurray

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

Prof McMurray is Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

View full profile

Mikhail Kosiborod

Saint Luke’s Mid America Heart Institute, Kansas City, US

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.

View full profile

The event ‘Current and Emerging Data on SGLT2 Inhibitors in Heart Failure’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

AVAILABLE CREDIT

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Renal Denervation In The Real World: Practical Guidance For New Users
  • 1 EBAC

Learning objectives

  • Assess the current global burden of resistant hypertension
  • Carry out appropriate assessments to identify resistant hypertension
  • Identify patients most likely to benefit from RDN
  • Recall the practical considerations for adopting RDN into routine practice
  • Recall the latest data on RDN from recent clinical trials
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Renal Denervation in Patients with Treatment-resistant Hypertension
  • 1.00 EBAC

Learning objectives

  • Describe the evidence to support the use of renal denervation as a treatment modality in patients with resistant hypertension
  • Understand renal denervation and how effective it is as a treatment option
  • Identify patients with resistant hypertension suitable for renal denervation
See more
Optimising Treatment of HF
  • 1.00 (EBAC)

Learning objectives

  • Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
  • Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
  • Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
  • Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
See more
Heart Failure & Cardiomyopathy: Highlights 2019-2021
  • 0.25 AMA PRA Category 1 Credit™

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarize results from ongoing trials with experimental treatments for HFrEF and HCM
See more